FDA Approved: ADAKVEO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for ADAKVEO (crizanlizumab) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)

Snippet

SUPPL AP for ADAKVEO (CRIZANLIZUMAB)